Evolus, INC Schedule 13G passive stakes

Soleus Capital entities and Guy Levy have filed a joint filing agreement for Schedule 13G concerning their beneficial ownership of Evolus, Inc. common stock.

The Vanguard Group has amended its Schedule 13G filing for Evolus Inc., reporting zero beneficial ownership following an internal realignment.

Timothy P. Lynch has disclosed a 9.9% beneficial ownership stake in Evolus, Inc., holding 6,425,726 shares of common stock.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, filed an amended Schedule 13G disclosing a shared beneficial ownership of 8.85% in Evolus, Inc. common stock.

Caligan Partners LP and David Johnson have reported a 6.4% beneficial ownership stake in Evolus, Inc., totaling 4,138,943 shares of common stock.

Timothy P. Lynch has increased his beneficial ownership in Evolus, Inc. to 7.9% of the common stock, totaling 5,133,776 shares.

Timothy P. Lynch has disclosed a 6.3% beneficial ownership stake in Evolus, Inc. common stock.

Perceptive Advisors and its affiliates have reduced their beneficial ownership in Evolus, Inc. to 3.8% of outstanding common stock.

Caligan Partners LP and David Johnson have disclosed a 5.2% beneficial ownership stake in Evolus, Inc., totaling 3,341,970 shares of common stock.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 5.90% in Evolus, Inc.'s common stock as of March 31, 2025.

Perceptive Advisors LLC and its affiliates have filed an amended Schedule 13G, reporting a continued passive beneficial ownership of 6.4% in Evolus, Inc.'s common stock.

Tang Capital Management, LLC and its affiliates, including Kevin Tang, have filed an amended Schedule 13G disclosing a collective beneficial ownership of 7.9% of Evolus, Inc.'s common stock as of March 31, 2025.

Medytox Inc., a South Korean company, has filed an amended Schedule 13G disclosing a 3.4% beneficial ownership stake in Evolus, Inc. as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.9% passive beneficial ownership stake in Evolus Inc. as of December 31, 2024.